The term rare diseases (RD) includes a wide heterogeneous group of disorders that can involve any human organ or system. In the last decade RD have been incorporated into the agenda of health-care providers and public-health authorities; however, many problems still remain to be solved and even addressed properly. Some of these issues refer to patient' care and management such as early diagnosis, quality of the information, access to treatment and rehabilitation, and appropriate multidisciplinary healthcare. Research is also necessary as it is the way to learn about mechanisms of diseases, improve diagnosis techniques and develop new therapeutic approaches. Research in psychological and social aspects of RD is also needed. Determinants for biomedical research in RD and orphan medicines affect basic science, clinical investigation, translational approaches, and transfer activities at the pharmaceutical and biotech companies, making the patient the focus of the triangle made up of the academy, hospitals and industry.

These determinants can be summarised as follows: i) The human factor: human resources for research need to incorporate new research teams into the field of RD and especially young scientists and physicians; ii) the financial factor: funds from public agencies, national and international, investment from the industry, and participation of charities and private foundations; iii) the training factor: interest in RD research has to be encouraged in young people at the graduate school of medicine, biological sciences, public health, and healthcare professionals to promote the professional and research interest; iv) core facilities: patients' registries and biobanks; v) the healthcare system: reorganisation of health resources and creation of centres of expertise to facilitate research into the clinical practice; vi) the social factor: promotion and empowerment of patients and their role as participants in clinical studies or clinical trials; vii) the political factor: RD as a main topic for public research.
